Tags

Type your tag names separated by a space and hit enter

Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?
Ann Surg Oncol. 2012 Oct; 19(10):3264-9.AS

Abstract

INTRODUCTION

Excisional biopsy is currently recommended for atypical ductal hyperplasia (ADH) diagnosed on core needle breast biopsy (CNB), due to risk of upstaging to invasive or in situ carcinoma (DCIS). The study goal was to identify patients who may potentially forego excisional biopsy if the risk of upstaging is low.

METHODS

We conducted a retrospective review of patients diagnosed with ADH on CNB who underwent excisional biopsy at one institution (5/2000-5/2011). We evaluated the upstaging rate and clinicopathologic factors associated with increased upstaging risk.

RESULTS

A total of 114 cases of ADH were diagnosed on CNB. The median patient age was 64 years. On mammography, a mass/density/area of distortion was present in 23 % of cases; calcifications were present in 77 %. Most biopsies (79 %) were performed stereotactically. Twenty lesions (18 %) were upstaged to infiltrating carcinoma (5 %) or DCIS (13 %). Residual ADH was present in 43 biopsies (38 %). On univariate analysis, significant variables associated with upstaging included age >50 years, a mass lesion on mammography, and shorter length of biopsy core (p < 0.05). No patient ≤50 years of age was upstaged. Three patients who were not upstaged (3 %) developed ipsilateral disease (2 DCIS and 1 infiltrating ductal carcinoma) at a median time of 37 months.

CONCLUSIONS

The rate of upstaging when ADH is diagnosed on CNB at our institution is 18 %, and routine excisional biopsy is currently recommended for all patients. However, patients <50 years old with focal atypia only and no residual calcifications postbiopsy may represent a low-risk group who could potentially avoid excisional biopsy.

Authors+Show Affiliations

Section of Surgical Oncology, Department of Surgery, Mayo Clinic Hospital, Mayo Clinic, Phoenix, AZ, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22878619

Citation

McGhan, Lee J., et al. "Atypical Ductal Hyperplasia On Core Biopsy: an Automatic Trigger for Excisional Biopsy?" Annals of Surgical Oncology, vol. 19, no. 10, 2012, pp. 3264-9.
McGhan LJ, Pockaj BA, Wasif N, et al. Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy? Ann Surg Oncol. 2012;19(10):3264-9.
McGhan, L. J., Pockaj, B. A., Wasif, N., Giurescu, M. E., McCullough, A. E., & Gray, R. J. (2012). Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy? Annals of Surgical Oncology, 19(10), 3264-9. https://doi.org/10.1245/s10434-012-2575-0
McGhan LJ, et al. Atypical Ductal Hyperplasia On Core Biopsy: an Automatic Trigger for Excisional Biopsy. Ann Surg Oncol. 2012;19(10):3264-9. PubMed PMID: 22878619.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy? AU - McGhan,Lee J, AU - Pockaj,Barbara A, AU - Wasif,Nabil, AU - Giurescu,Marina E, AU - McCullough,Ann E, AU - Gray,Richard J, Y1 - 2012/08/10/ PY - 2012/06/08/received PY - 2012/8/11/entrez PY - 2012/8/11/pubmed PY - 2013/2/15/medline SP - 3264 EP - 9 JF - Annals of surgical oncology JO - Ann Surg Oncol VL - 19 IS - 10 N2 - INTRODUCTION: Excisional biopsy is currently recommended for atypical ductal hyperplasia (ADH) diagnosed on core needle breast biopsy (CNB), due to risk of upstaging to invasive or in situ carcinoma (DCIS). The study goal was to identify patients who may potentially forego excisional biopsy if the risk of upstaging is low. METHODS: We conducted a retrospective review of patients diagnosed with ADH on CNB who underwent excisional biopsy at one institution (5/2000-5/2011). We evaluated the upstaging rate and clinicopathologic factors associated with increased upstaging risk. RESULTS: A total of 114 cases of ADH were diagnosed on CNB. The median patient age was 64 years. On mammography, a mass/density/area of distortion was present in 23 % of cases; calcifications were present in 77 %. Most biopsies (79 %) were performed stereotactically. Twenty lesions (18 %) were upstaged to infiltrating carcinoma (5 %) or DCIS (13 %). Residual ADH was present in 43 biopsies (38 %). On univariate analysis, significant variables associated with upstaging included age >50 years, a mass lesion on mammography, and shorter length of biopsy core (p < 0.05). No patient ≤50 years of age was upstaged. Three patients who were not upstaged (3 %) developed ipsilateral disease (2 DCIS and 1 infiltrating ductal carcinoma) at a median time of 37 months. CONCLUSIONS: The rate of upstaging when ADH is diagnosed on CNB at our institution is 18 %, and routine excisional biopsy is currently recommended for all patients. However, patients <50 years old with focal atypia only and no residual calcifications postbiopsy may represent a low-risk group who could potentially avoid excisional biopsy. SN - 1534-4681 UR - https://www.unboundmedicine.com/medline/citation/22878619/Atypical_ductal_hyperplasia_on_core_biopsy:_an_automatic_trigger_for_excisional_biopsy L2 - https://dx.doi.org/10.1245/s10434-012-2575-0 DB - PRIME DP - Unbound Medicine ER -